Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12610000198022
Ethics application status
Not yet submitted
Date submitted
26/01/2010
Date registered
9/03/2010
Date last updated
9/03/2010
Type of registration
Prospectively registered

Titles & IDs
Public title
Cannabis and Stroke Study (CASS): A comparison of positive drug screens for cannabis and amphetamines in stroke versus nonstroke patients
Scientific title
Study comparing the proportion of positive drug screens for cannabis and amphetamines in stroke and nonstroke patients aged between 45 and 55 years
Secondary ID [1] 1348 0
Nil
Universal Trial Number (UTN)
Trial acronym
CASS
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Stroke 256677 0
Drug use (cannabis and amphetamines) 256707 0
Condition category
Condition code
Neurological 256834 256834 0 0
Other neurological disorders
Stroke 256862 256862 0 0
Ischaemic
Stroke 256863 256863 0 0
Haemorrhagic

Intervention/exposure
Study type
Observational
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
Nonstroke patients aged 45- 55 years will have urine drug screen performed for cannabis and amphetamines. One urine sample drug screen at time of admisssion. Duration of study two years
Intervention code [1] 255908 0
Not applicable
Comparator / control treatment
Stroke patients aged 45 - 55 years from medical records 2009 to 2011
Control group
Historical

Outcomes
Primary outcome [1] 257699 0
Proportion of positive urine screens for cannabis and amphetamines in stroke and nonstroke patients
Timepoint [1] 257699 0
one urine sample drug screen at time of admission
Secondary outcome [1] 263045 0
Nil
Timepoint [1] 263045 0
Nil

Eligibility
Key inclusion criteria
age 45- 55 years
admission under general medicine with diagnosis other than stroke and a urine sample taken as part of their care
Minimum age
45 Years
Maximum age
55 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Stroke

Study design
Purpose
Screening
Duration
Cross-sectional
Selection
Convenience sample
Timing
Prospective
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
1/04/2010
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
70
Accrual to date
Final
Recruitment outside Australia
Country [1] 2440 0
New Zealand
State/province [1] 2440 0

Funding & Sponsors
Funding source category [1] 256406 0
Hospital
Name [1] 256406 0
Neurology Pool Fund
Country [1] 256406 0
New Zealand
Primary sponsor type
Individual
Name
Professor Alan Barber
Address
Department of Medicine
University of Auckland
Level 12, Support Building
Auckland City Hospital
2 Park Road
Grafton
Auckland 1023
Country
New Zealand
Secondary sponsor category [1] 251713 0
None
Name [1] 251713 0
Address [1] 251713 0
Country [1] 251713 0

Ethics approval
Ethics application status
Not yet submitted
Ethics committee name [1] 258463 0
Ethics committee address [1] 258463 0
Ethics committee country [1] 258463 0
Date submitted for ethics approval [1] 258463 0
27/01/2010
Approval date [1] 258463 0
Ethics approval number [1] 258463 0

Summary
Brief summary
The hypothesis is that cannabis and amphetamine use can precipitate stroke. The Aim is to compare the proportion of positive urine drug screens of a group of young stroke patients with a group of nonstroke patients
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 30767 0
Address 30767 0
Country 30767 0
Phone 30767 0
Fax 30767 0
Email 30767 0
Contact person for public queries
Name 14014 0
Heidi Pridmore
Address 14014 0
Neurology Research Unit
Department of Medicine
Level 12, Support Building
Auckland City Hospital
2 Park Road
Grafton, Auckland 1023
Country 14014 0
New Zealand
Phone 14014 0
+64 9 9231660
Fax 14014 0
Email 14014 0
[email protected]
Contact person for scientific queries
Name 4942 0
Heidi Pridmore
Address 4942 0
Neurology Research Unit
Department of Medicine
Level 12, Support Building
Auckland City Hospital
2 Park Road
Grafton
Auckland 1023
Country 4942 0
New Zealand
Phone 4942 0
+64 9 9231660
Fax 4942 0
Email 4942 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
Dimensions AICannabis, Ischemic Stroke, and Transient Ischemic Attack2013https://doi.org/10.1161/strokeaha.113.001562
N.B. These documents automatically identified may not have been verified by the study sponsor.